Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy

Figure 1 Wharton’s Jelly–derived mesenchymal stem cell flow cytometry, positive marker values (CD90, CD105, CD73 and CD44) are above 95%. Negative marker values (CD45, CD34, CD19, CD11B, human leukocyte antigen-DR and CD14) are below 2%. HLA: Human leukocyte antigen.

Figure 2 Detection of the differentiation potential of Wharton’s Jelly–derived-mesenchymal stem cells. A and B: Wharton's Jelly Derived-mesenchymal stem cells (WJ-MSCs) were cultured without adipogenic induction and cultured for 3 wk in adipogenic differentiation medium. Adipogenic differentiation was evidenced by the formation of lipid vacuoles with oil red O staining; C and D: WJ-MSCs were cultured without osteogenic induction and cultured for 3 wk in osteogenic differentiation medium. Osteogenic differentiation was evidenced by the detection of calcium deposits with Alizarin red staining; E and F: WJ-MSCs were cultured without chondrogenic induction and cultured for 3 wk in chondrogenic differentiation medium. Chondrogenic differentiation was evidenced with Alcian blue staining.

Figure 3 Change observed in the pre-test and post-test averages. A: Change observed in the pre-test and post-test averages of the patients' Wee functional independence measure motor score and cognitive score values; B: Change observed in the pre-test and post-test averages of the patients' Gross motor function classification system and manual ability classification system values. WeeFIM: Wee functional independence measure motor; GMF-CS: Gross motor function classification system; MA-CS: Manual ability classification system.